Gain-of-Function Mutant p53 Together with ERG Proto-Oncogene Drive Prostate Cancer by Beta-Catenin Activation and Pyrimidine Synthesis

Researchers demonstrated that TMPRSS2-ERG fusion and TP53 mutation / deletion co-occur in prostate cancer patient specimens and this co-occurrence accelerates prostatic oncogenesis.